DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

BSX·Boston Scientific Corporation

$.
-. (-.%)
Pre-Market
High
$57.88
Open
$57.76
Market Cap
85.88B
52W High
$109.50
Low
$57.68
P. Close
$57.92
P/E
24.09
52W Low
$52.52
Fwd P/E
15.35
Mean Target
$83.47
Technical Score (1D)
23
SELL
News Sentiment
48
MIXED
Boston Scientific has issued voluntary recalls for its LUX-Dx II arrhythmia detector and alarm devices, prompted by FDA reports detailing failures in data collection and monitoring of critical cardiac events. These recalls are linked to device programming discrepancies that affect the reliability of arrhythmia monitoring. This situation introduces operational and quality control risks for the company, potentially impacting patient care and clinician confidence. Investors will be watching for updates on the scope of these recalls and the company's response to the FDA's findings.
Earnings Summary
Boston Scientific Corporation is a global medical device manufacturer specializing in interventional medical specialties, operating within the Healthcare sector's Medical Devices industry. The company develops, manufactures, and markets a diverse portfolio of devices for gastrointestinal, urological, neurological, and cardiovascular treatments, including chronic pain management and heart rhythm management. Boston Scientific's recent earnings performance demonstrates consistent positive results. In Q1 2026, the company reported actual EPS of 0.80 against an estimate of 0.78722, with revenue of 5.203 billion against an estimate of 5.171 billion. This follows Q4 2025, where actual EPS was 0.80 versus an estimate of 0.7873, and revenue was 5.286 billion against an estimate of 5.333 billion. Prior to this, Q3 2025 showed actual EPS of 0.75 against an estimate of 0.71366, and Q2 2025 had actual EPS of 0.75 against an estimate of 0.72522. Boston Scientific has a strong beat pattern, exceeding EPS estimates in all reported quarters from Q2 2025 through Q1 2026, and revenue estimates in Q1 2026. The company has shown a consistent upward trajectory in both EPS and revenue growth over the last several quarters, with revenue accelerating from Q1 2025 through Q3 2025 before a slight dip in Q4 2025 and a rebound in Q1 2026. Year-over-year, the company has demonstrated robust growth, consistently beating analyst expectations for both earnings and revenue. Recent news highlights positive pivotal trial results for Boston Scientific's SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter, which will support an upcoming regulatory submission. Insider transactions show directors increasing their share ownership, potentially signaling confidence. Analysts maintain positive ratings, with Baird reiterating an Outperform rating and Leerink Partners raising its price target. Investors will be watching for the regulatory submission outcome for the SEISMIQ 4CE device and continued strong revenue growth in the upcoming quarters. Key will be the company's ability to sustain its beat streak and capitalize on new product introductions within its diverse medical device portfolio.

EPS

EstBeatMiss
$0.65$0.70$0.75$0.80$0.86Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.83 - -
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%
Q2'25$0.73$0.75+3.4%
Q1'25$0.67$0.75+11.5%

Revenue

EstBeatMiss
$4.6B$4.8B$5.0B$5.3B$5.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -
Q2'25 - $5.1B -
Q1'25 - $4.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BSX Stock Snapshot

BSX is currently trading at $57.68, giving Boston Scientific Corporation a market cap of 85.88B and a P/E ratio of 24.1. Today's range spans $57.68–$57.88, with shares opening at $57.76 and moving down $0.24 (0.4%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 48/100.

Over the past year BSX has traded between $52.52 and $109.50 - the current price is +9.8% off the 52-week low and -47.3% from the high. 43 analysts cover the stock with a Buy consensus and a mean 12-month target of $83.47 (range $60.00–$106.00), implying upside of +44.7%.

Macro sensitivity explains some of BSX's bearish setup (23/100, SELL) - at 85.88B in Healthcare market cap, interest rate shifts, currency moves, or commodity price changes can create fundamental headwinds that compound the technical deterioration. Sentiment: neutral (48/100). Price: $57.68 (near 52-week lows). The current P/E ratio stands at 24.1. Annual range: $52.52–$109.50. The question for investors is whether the macro driver is transient or structural - because the answer determines whether this is a tradeable dip or a deeper re-rating.

The current SELL phase for BSX (23/100) at $57.68 (near 52-week lows) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 48/100 (neutral) confirms that news flow is not providing a counternarrative. At 85.88B in Healthcare capitalization, BSX has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $52.52–$109.50 range.